ZYBT Market Analysis

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)$-0.21-79.6% YoY
Profit margin-60.0%HEALTHCARE
Market cap$65.4MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
1.78
P/S (TTM)
0.56
EV/EBITDA
21.76

Profitability & growth

ROE (TTM)
-25.2%
Operating margin
-77.0%
Revenue growth YoY
-40.9%
Dividend yield
Beta
Last earnings
Dec 12, 2025 · Estimate $0.00 · Reported $-0.46
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Zhengye Biotechnology Holding Limited Ordinary Shares

Company profile

Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm specializing in the development and commercialization of advanced biopharmaceutical products aimed at addressing critical medical needs. With a robust pipeline and proprietary technologies, ZYBT is well-positioned to enhance treatment outcomes across multiple therapeutic areas. The company's commitment to rigorous research and development, coupled with a focus on quality and innovation, underscores its potential for sustainable growth and value creation for investors in the competitive biotechnology…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
NO.1 LIANMENG ROAD, JILIN, CHINA
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$65.4M
Shares outstanding$47.4M
52W high$10.12
52W low$0.62

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer